Evidence map›Paper›PMID 42676515›Full record

ArticleFrontiers in immunology2026

Early and sex-specific dynamic changes of the modified Glasgow Prognostic Score correlate with survival and immunotoxicities in patients undergoing allogeneic hematopoietic stem cell transplantation.

Hannah Thurisch, Kathrin C Althoff, Katharina Leuchte, Wajma Shahbaz, Maximilian A Funk, Martin E Kirmaier, Amar Hadzic, Sabine Oganesian, Adriano Carboniero, Ludovica Vona and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hannah ThurischCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Kathrin C AlthoffDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Katharina LeuchteDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Wajma ShahbazCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Maximilian A FunkCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Martin E KirmaierCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Amar HadzicCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Sabine OganesianCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Adriano CarbonieroCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Ludovica VonaCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Caroline GeierCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Lena MuschikCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
David M Cordas Dos SantosCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Michael von Bergwelt-BaildonDepartment of Medicine III and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany.
Udo HoltickDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Christof ScheidDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Sebastian TheurichCancer and Immunometabolism Research Group, Gene Center, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risk assessment before allogeneic hematopoietic stem cell transplantation (alloHSCT) is essential to estimate treatment-related morbidity and mortality; the hematopoietic cell transplantation-comorbidity index (HCT-CI) is widely used. The modified Glasgow Prognostic Score (mGPS), reflecting systemic inflammation and nutritional status, is a validated prognostic marker in solid tumors, but ill-defined in alloHSCT. We evaluated the prognostic impact of mGPS before and early after alloHSCT on overall survival (OS), non-relapse mortality (NRM), and acute graft-versus-host disease (aGvHD). We analyzed 442 consecutive alloHSCT patients (2012-2017, University Hospital Cologne). Outcomes were assessed by mGPS pre-transplant (preTx), at day+30, and by dynamic changes (Δ

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdolescentAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentSex FactorsTransplantation, HomologousYoung Adultallogeneic hematopoietic stem cell transplantationgraft-versus-host diseaseimmunonutritional statusinflammationmetabolismrisk assessment

Identifiers

PMID42676515
PMCPMC13526978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.